Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
This suggests that the type I IFN response may play a crucial role in supporting a robust immune response against cancer
Thoo Neuromuscular Disease Neuromuscular Disease Drug: RGX-202 Company: RegenxBio Indication: Duchenne muscular dystrophy (DMD) Stage: Phase III Background: RGX-202 uses an AAV8 vector delivering a novel micro-dystrophin gene, including the C-terminal domain, which offers a potential improved dystrophin stability and muscle membrane integrity in DMD patients
What matters clinically is that no single peptide does everything
Consult healthcare professionals for personalized advice
US$ 20.50
US$ 28.45
US$ 22.04
US$ 20.09
US$ 28.15
